GW 468816

Drug Profile

GW 468816

Alternative Names: 468816; GW-468816

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; National Institute on Drug Abuse
  • Class Antimigraines; Smoking cessation therapies
  • Mechanism of Action Glycine antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Smoking withdrawal
  • Discontinued Migraine

Most Recent Events

  • 10 Dec 2009 Efficacy data from three clinical trials presented at the 48th Annual Meeting of the American College of Neuropsychopharmacology (ACNP-2009)
  • 11 Jan 2008 Phase II development is ongoing
  • 30 Apr 2002 Discontinued - Phase-I for Migraine in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top